Persistence and Adverse Events of Biological Treatment in Adult Patients With Juvenile Idiopathic Arthritis


Juan José Bethencourt Baute; Carlos Sanchez-Piedra; Dolores Ruiz-Montesinos; Marta Medrano San Ildefonso; Carlos Rodriguez-Lozano; Eva Perez-Pampin; Ana Ortiz; Sara Manrique; Rosa Roselló; Victoria Hernandez; Cristina Campos; Agustí Sellas; Walter Alberto Sifuentes-Giraldo; Javier García-González; Fernando Sanchez-Alonso; Federico Díaz-González; Juan Jesús Gómez-Reino; Sagrario Bustabad Reyes; on behalf of the BIOBADASER study group


Arthritis Res Ther. 2018;20(227) 

In This Article

Abstract and Introduction


Background: Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood.

Methods: All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, and SDs were used to describe the population. Incidence rates and 95% CIs were calculated to assess adverse events. Kaplan-Meier analysis was used to compare the drug survival rates.

Results: A total of 469 patients (46.1% women) were included. Their mean age at diagnosis was 9.4 ± 5.3 years. Their mean age at biologic treatment initiation was 23.9 ± 13.9 years. The pattern of use of biologics during their pediatric years showed a linear increase from 24% in 2000 to 65% in 2014. Biologic withdrawal for disease remission was higher in patients who initiated use biologics prior to 16 years of age than in those who were older (25.7% vs 7.9%, p < 0.0001). Serious adverse events had a total incidence rate of 41.4 (35.2–48.7) of 1000 patient-years. Patients younger than 16 years old showed significantly increased infections (p < 0.001).

Conclusions: Survival and suspension by remission of biologics were higher when these compounds were initiated in patients with JIA who had not yet reached 16 years of age. The incidence rate of serious adverse events in pediatric vs adult patients with JIA treated with biologics was similar; however, a significant increase of infection was observed in patients under 16 years old.